Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame themselves for it.

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a review published online Jan. 7 in the Annals of Internal Medicine.

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug spending. But thus far, the data don’t show this.

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL from inception through October 4, 2024.

Investigational once-weekly retatrutide yielded the greatest weight loss of all GLP-1 receptor agonists, up to 22.1% after 48 weeks in adults with overweight or obesity and withou

On the surface, the formula for weight loss seems simple: eat less and move more. But giving that advice to someone with obesity is like telling someone with depression to cheer up. Weight loss isn't easy,

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high costs—often exceeding $1,000 per month—put them out of reach for many Americans whose

Weight loss tops many folks' list of New Year's resolutions, and lots of people are turning to cutting-edge weight-loss drugs like Ozempic to help them drop excess pounds.

In January 2023, the world was abuzz with stories of a revolutionary weight-loss drug – a simple, self-administered injection that promised to transform the lives of those struggling with obesity. The click-baity headlines surrounding Ozempic,